文献速递肝病消化道肿瘤与早癌

脂肪肝高风险放大HSD17B13变异降低ALT效应

High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
PubMed 文献 · Hepatology · 2019-08-09

在丹麦一般人群111,612人中,HSD17B13 rs72613567:TA与血浆ALT阶梯式降低相关,TA/TA纯合子较T/T纯合子ALT降低达1.3 U/L。每增加一个TA等位基因,肝硬化和肝细胞癌风险分别降低15%和28%,肝相关死亡率降低达33%(肝硬化患者达49%)。肥胖、饮酒及脂肪肝遗传风险增加可放大该变异的降ALT效应。

要点

  • HSD17B13 rs72613567:TA与血浆ALT阶梯式降低相关,TA/TA纯合子较T/T纯合子降低达1.3 U/L。
  • 每增加一个TA等位基因,肝硬化和肝细胞癌风险分别降低15%和28%。
  • 肥胖、饮酒及PNPLA3/TM6SF2脂肪肝遗传风险增加可放大该变异的降ALT效应。

核心结论

  • 在丹麦一般人群中,脂肪肝高风险可放大HSD17B13 rs72613567:TA的降ALT效应。

研究设计与样本

  • 研究纳入丹麦一般人群111,612人,其中肝硬化497例、肝细胞癌113例,分析rs72613567与血浆ALT、临床肝病及死亡率的相关性。

主要发现

  • HSD17B13 rs72613567:TA与血浆ALT阶梯式降低相关,TA/TA纯合子较T/T纯合子降低达1.3 U/L。
  • 每增加一个TA等位基因,肝硬化风险降低15%,肝细胞癌风险降低28%。
  • 前瞻性分析中,TA等位基因与一般人群肝相关死亡率降低达33%相关,与肝硬化患者肝相关死亡率降低达49%相关。
  • 肥胖、饮酒及脂肪肝遗传风险增加可放大rs72613567:TA的降ALT效应。
  • 在瘦且不饮酒且肝脂肪变性遗传风险低的个体中,TA等位基因仅与 marginally lower ALT 相关;而在最肥胖者、重度饮酒者及携带三个或四个PNPLA3和TM6SF2脂肪变性等位基因者中,TA/TA纯合子较T/T纯合子血浆ALT降低12%至18%。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A common loss-of-function variant in HSD17B13 (rs72613567:TA) was recently found to protect from chronic liver disease. Whether the variant confers protection from specific risk factors for liver disease is unclear. We tested the association of rs72613567 with plasma levels of alanine transaminase (ALT) and clinical liver disease and mortality in 111,612 individuals from the Danish general population, including 497 with cirrhosis and 113 with hepatocellular carcinoma. HSD17B13 rs72613567:TA was associated with stepwise lower levels of plasma ALT of up to 1.3 U/L in TA/TA homozygotes versus T/T homozygotes. For each TA-allele, the risk of cirrhosis and hepatocellular carcinoma was reduced by 15% and 28%, respectively. In prospective analyses, the TA-allele was associated with up to 33% lower rates of liver-related mortality in the general population, and with up to 49% reduced liver-related mortality in patients with cirrhosis. The ALT-lowering effect of rs72613567:TA was amplified by increasing adiposity, alcohol consumption, and genetic risk of fatty liver disease. The TA-allele was associated with only marginally lower ALT in lean nondrinkers with low genetic risk of hepatic steatosis. In contrast, compared with T/T homozygotes, TA/TA homozygotes had 12% to 18% lower plasma ALT among the most obese, in heavy drinkers, and in individuals carrying three or four steatogenic alleles in patatin-like phospholipase domain-containing protein 3 (PNPLA3) and transmembrane 6 superfamily 2 (TM6SF2). Conclusion: High risk of fatty liver disease amplifies the ALT-lowering effect of HSD17B13 rs72613567:TA in the Danish general population.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Gellert-Kristensen H, Nordestgaard BG, Tybjaerg-Hansen A, et al. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant. Hepatology. 2019. PMID: 31155741. doi:10.1002/hep.30799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。